According to FutureWise analysis the market for dravet syndrome in 2023 is US$ 0.55 billion, and is expected to reach US$ 1.12 billion by 2031 at a CAGR of 9.40%.
Dravet syndrome is an autosomal dominant, genetic disorder that causes a devastating form of epilepsy. It is often triggered by high temperatures or fever. Dravet syndrome is characterized by non-febrile and prolonged febrile seizures in the first year of a child’s life. The disease can progress to other seizure types such as myoclonic or partial seizures, psychomotor delay, and ataxia. It can be characterized by cognitive impairment, motor deficits, and behavioral disorders. Behavioral deficiencies include hyperactivity, impulsiveness, or in rare cases autistic-like behaviors. Dravet syndrome can also be associated with sleep disorders, such as somnolence or insomnia. As the disease progresses, Dravet syndrome patients experience more severe seizures. It is difficult to find treatments due to the wide range of seizures and resistance to medications. Dravet syndrome is most common in the first year of life. It often begins around six months old with frequent febrile seizures (fever-related seizures). Dravet syndrome is characterized by the slow development of language, and motor skills, hyperactivity, sleep difficulties, chronic infections, growth and balance problems, difficulty relating to others, and difficulty with language and social interaction. Dravet syndrome is a chronic condition that can not be reversed. Children diagnosed with Dravet need to be cared for by parents who are patient and able to monitor their progress.
Due to the anticipated launch of new therapies, the market dynamics for Dravet syndrome will see a positive shift. This includes the development of new drugs like stiripentol and cannabidiol. The global Dravet syndrome market is expected to grow due to the availability of favorable reimbursement policies in both the early and late stages of therapeutic product development. Other factors, such as an increase in government support for research and development and a better regulatory framework in the healthcare industry, can also help to boost the market growth. Research activities related to Dravet disorder are not subject to stringent regulations. The market is also growing due to increased funding and acceptance of Dravet-syndrome therapies. The market's growth is impeded by a lack of awareness, side effects, poor healthcare systems in developing countries, and low availability of therapeutic agents and drugs.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Dravet Syndrome Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Dravet Syndrome Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.